Although VIALE-A showed no statistically significant survival benefit for venetoclax and azacitadine versus azacitidine in TP53 mutated patients, [112] synergism of CD47 blockade and Bcl-2 targeting therapy may be possible as seen in in chronic lymphocytic leukemia [113]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.